General Information of Drug (ID: DMAKP20)

Drug Name
eicosatetranoic acid Drug Info
Synonyms
ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; eicosatetranoic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1780
ChEBI ID
CHEBI:94483
CAS Number
CAS 1191-85-1
TTD Drug ID
DMAKP20

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [4]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [5]
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [6]
Ciprofibrate DMGC5DB Hyperlipoproteinemia 5C80 Approved [5]
Pemafibrate DMD1VZL Hyperlipidemia 5C80.Z Approved [7]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [8]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [9]
CS-038 DM67P0F Type-2 diabetes 5A11 Phase 3 [10]
TESAGLITAZAR DMGRBN5 Type-1 diabetes 5A10 Phase 3 [11]
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [13]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [14]
Dextropropoxyphene DM23HCX Pain MG30-MG3Z Approved [15]
Selenium DM25CGV N. A. N. A. Approved [16]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [17]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [18]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [19]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [20]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [21]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [22]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2669).
2 PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 1997 Jul;378(7):651-5.
3 Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem Biophys Res Commun. 2001 Jun 22;284(4):1065-70.
4 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
5 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
6 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
7 Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
8 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
9 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
10 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
11 Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
12 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
13 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
14 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
15 Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
16 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
17 Human carboxylesterase 1: from drug metabolism to drug discovery. Biochem Soc Trans. 2003 Jun;31(Pt 3):620-4. doi: 10.1042/bst0310620.
18 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
19 Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol. 2003 Apr;10(4):341-9. doi: 10.1016/s1074-5521(03)00071-1.
20 Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
21 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
22 Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.